AKT1 and cancer: Based on experiments with gene and protein assays, gene sequencing, and drug sensitivity testing, we found that the differences between the models may involve activation of the PTEN/PI3K‐AKT pathway, cancer‐related pathways, and synthetic and metabolism‐related molecules.